Rigel Pharma: Q3 Earnings Showcase Robust Growth
2025-11-26 08:15:38 ET
Rigel Pharma (NASDAQ: RIGL ) is a mature and profitable biotech, founded in 1996 and headquartered in South San Francisco. The company has three FDA approved medicines focusing in hematologic disorders and cancer. These drugs were approved in 2018, 2020 and 2022. Sales growth was initially subdued but, in the last several quarters, revenue growth has accelerated. This was led by Tavalisse which sold $113.3M in the first three quarters of 2025, 54% growth compared to the same period in 2024. In 2024, the drug grew sales by 11.8%, thus what had appeared to be a mature franchise suddenly become a major growth catalyst....
Read the full article on Seeking Alpha
For further details see:
Rigel Pharma: Q3 Earnings Showcase Robust Growth
NASDAQ: RIGL
RIGL Trading
-3.13% G/L:
$26.0825 Last:
96,605 Volume:
$26.87 Open:
